According to Renub Research’s latest report, “Japan Diabetes Market, By Insulin Pump, CGM, Self-Monitoring Blood Device and Company Analysis” the Japan Diabetes Market to grow with a CAGR of 2.73% from 2022 to 2028. Japan has one of the largest older populations in the world, which is more susceptible to the onset of type 2 diabetes. Diabetes is a no infectious disease caused by high blood glucose levels. Over time, it can lead to serious heart, brain, blood vessels, eye, kidney, and nerve damage. With a rising aging population, lifestyle changes, increasing overweight, and the prevalence of diabetic patients increasing, have significantly boosted the market. According to World Health Organization, Diabetes Mellitus deaths in Japan reached 5,433 deaths.
Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/japan-diabetes-market-p.php
Rapidly Increasing Aging Population creates Type-2 Diabetes Prevalence in Japan
This high prevalence of type 2 diabetes is associated with a significant economic burden, on aging population, and the costs of diabetes increase in patients with co-morbidities. In addition, the majority of type 2 diabetes had associated with a high intake of traditional Japanese foods, such as soybean products, seaweed, and Japanese pickles, increased longevity, COVID pandemic, lifestyle changes, lack of screening tests & public awareness. In 2021, the Japanese Circulation Society and the Japan Diabetes Society also emphasized the importance of biomarker measurement in diagnosing cardiovascular diseases in people with type 2 diabetes.
In Japan, the incidence rate of type 1 diabetes in children aged 0-14 increased over time. Most type 1 patient stay in a hospital for 2-4 weeks at their diagnosis for the initial treatments, exams, and diabetes education. In 2019, a country-wide campaign called ‘Sche1sstyp’ was initiated by the Germany-based research canter Helmholtz Zentrum München. The campaign addresses the prevention and early detection of type 1 diabetes.
Advanced Technology will create more demand for SMBG Devices
Japan is one of the high-potential markets for developing diabetes care devices. Monitoring and managing blood glucose levels are rising to avoid negative consequences. The ease of doing, patient satisfaction, and cost-effectiveness create more demand for SMBG devices. SMBG provides rapidly accurate blood glucose readings, which offers significant benefits to diabetics and, ultimately, financially, their healthcare providers.
In addition, the market had essentially driven by the increasing number of diabetic patients, the availability of blood glucose meters at a nominal cost, and active reimbursement policies of patients. In 2021, AstraZeneca’s Farxiga had approved in Japan. The drug is a blockbuster in the country and became a selling diabetes drug in Japan.
Although the government of Japan has been striving to control diabetes and other lifestyle-related diseases through the Heath Promotion Program called “Healthy Japan 21” campaign in 2013. The Strategy for extending healthy life expectancy that sets concrete targets across disease areas, including diabetes, which the mission to reduce the number of people who will develop diabetes, as well as the number of people with diabetes who discontinue treatment, have unhealthy blood sugar levels, and formulate diabetes-related complications.
It can further strengthen primary care and governance across the entire pathway of CVD and diabetes care. Using a variety of policy instruments to improve the quality of services along the whole path, such as through the introduction of integrated care models, financial incentives for improved quality and performance, benchmarking, and target setting. In Japan, the number of dialyzes populations is the highest in the OECD d the number of dialyze populations in Japan due to low-of-pocket payment and highly effective and established clinical standards for dialysis. However, it provides health insurance to citizens and non-citizens residing in Japan for more than a year through its universal healthcare system.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=japan-diabetes-market-p.php
Where the insurance coverage is determined on a per-workplace identifying industries and workplaces with a high risk of diabetes and implementing efficient primary and secondary prevention programs will contribute to curbing healthcare expenditures. As such, diabetes prevention continues to be a significant public initiative in Japan.
Competitive Landscape:-
Japan Diabetes companies include Medtronic, Insulet Corporation, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, and Tandem Diabetes Care.
- In March 2022, Quantum Operation Inc., a Tokyo-based healthcare IoT start-up, presented the world’s first non-invasive glucose monitor capable of continuous measurement. It measures the blood sugar from the wrist without any pricks.
Market Summary:-
- By Devices: – The Report covers the Japan Diabetes Market by devices from 3 viewpoints. (SMBG Market by Test Strips, Lancet, Meter, Blood Glucose Device Users & Reimbursement) Continuous Glucose Monitoring (CGM Market by Components, Glucose Sensor, Transmitter, CGM User, Reimbursement), Insulin Pump (Users, Market & Differentiation Points of Insulin Pump Products, Training Model for Patients & HCP, Reimbursement Policies) and Reimbursement Policies), respectively.
- The company report covers the Japan Diabetes Market from Three viewpoints. Medtronic, Insulet Corporation, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, and Tandem Diabetes Care.
Browse Related Report:
France Diabetes Market : https://www.renub.com/france-diabetes-market-p.php
US Diabetes Market : https://www.renub.com/united-states-diabetes-market-p.php
UK Diabetes Market : https://www.renub.com/united-kingdom-diabetes-market-p.php
Canada Diabetes Market : https://www.renub.com/canada-insulin-pump-cgm-market-p.php
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Address: 225 Kristie Ln, Roswell, GA 30076
Email: [email protected]
LinkedIn: https://in.linkedin.com/company/renub-research
Web: www.renub.com